LivaNova to Present New Data on Vagus Nerve Stimulation Therapy System at the American Epilepsy Society 2019 Annual Meeting
The first presentation is a sub-analysis of stimulation parameters that can determine the efficacy of VNS Therapy in patients with super-refractory status epilepticus (SRSE). SRSE is a type of refractory status epilepticus that continues despite 48 hours of anesthetic therapy and has high mortality and morbidity rates.1,2,3
Data on the seizure burden in patients with Lennox-Gastaut Syndrome (LGS) who later undergo VNS Therapy implantation will also be presented. LGS is a rare type of epilepsy with different types of seizures that can be hard to control and typically starts in childhood.4
“Our VNS Therapy System has successfully treated more than 100,000 patients around the world,” said
The data will be displayed on posters
“Stimulation Parameters in Acute Vagus Nerve Stimulation for Super Refractory Status Epilepticus”
“Demographics and Seizure Burden in Patients with Lennox Gastaut Syndrome in the VNS Therapy Outcomes Registry”
For more information about the VNS Therapy System, visit the
Important Safety Information
About VNS Therapy® for Epilepsy
VNS Therapy is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children 4 years of age and older. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. VNS Therapy has not been evaluated by
INTENDED USE / INDICATIONS –
Epilepsy—The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.
Commonly reported side effects are hoarseness, shortness of breath, sore throat and coughing. Side effects typically occur during stimulation and decrease over time.
See full safety information at VNSTherapy.com/safety.
For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding and our approach to treating drug-resistant epilepsy using VNS Therapy. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended
- Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia 2011;52(Suppl 8):53e6. https://doi.org/10.1111/j.1528-1167.2011.03238.x.
- Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;
- Kantanen AM, Reinikainen M, Parviainen I, Ruokonen E, Ala-Peijari M, Backlund T, et al. Incidence and mortality of super-refractory status epilepticus in adults. Epilepsy Behav 2015;49:131e4. https://doi.org/10.1016/j.yebeh.2015.04.065.
Epilepsy Foundation. Lennox-Gastaut Syndrome (LGS). Accessed November 13, 2019.
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications